A. Porsteinsson

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A.p. Porsteinsson, Anton P. Porsteinsson, A. P. Porsteinsson, Anton P Porsteinsson, A Porsteinsson, A P Porsteinsson, A. Porsteinsson, Anton Porsteinsson
Publication record
285 papers · 14,968 citations · H-index 55

PAPERS

Deep learning enhanced ALPS reveals genetic and environmental factors of brain glymphatic function
20260 citationsauthor #406
Blood biomarkers for Alzheimer's disease are correlated with measures of agitation and cognition in a randomized trial assessing the effects of escitalopram on agitation
20260 citationsauthor #8
Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease.
20261 citationsauthor #2
Genetic modifiers of APOE-ε4-associated cognitive decline.
20260 citationsauthor #149
Peripheral biomarkers associated with apathy and predicting response to methylphenidate: Secondary analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET2) study.
20260 citationsauthor #13
Developing Topics.
20250 citationsauthor #6
Human lifespan changes in the brain’s functional connectome
202557 citationsauthor #201
Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial
20256 citationsauthor #10
Developing Topics.
20250 citationsauthor #4
Fosgonimeton in mild-to-moderate Alzheimer's disease
20250 citationsauthor #1
Developing Topics.
20250 citationsauthor #6
Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer's disease: A factor analysis.
20252 citationsauthor #5
Dynamic proportional loss of functional connectivity revealed change of left superior frontal gyrus in subjective cognitive decline: an explanatory study based on Chinese and Western cohorts
20251 citationsauthor #148
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.
202513 citationsauthor #14
Association between self-reported multimorbidity and longitudinal brain Aβ deposition in Alzheimer’s disease
20251 citationsauthor #100
Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease
20255 citationsauthor #12
Targeting SEMA4D/PLXN signaling through reactive glia as a common pathology for the treatment of neurodegenerative disorders
20250 citationsauthor #11
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials
20250 citationsauthor #11
Developing Topics.
20250 citationsauthor #1
Relationships of PGRN with sTREM2 in AD continuum and non-AD pathophysiology and their reciprocal roles in modulating amyloid pathology: two population-based study
20253 citationsauthor #211
Clinical Manifestations.
20250 citationsauthor #3
Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders.
20252 citationsauthor #13
Developing Topics.
20250 citationsauthor #7
Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment
202531 citationsauthor #26
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
20251 citationsauthor #4
Uncovering Lipid Biomarkers Linked to Methylphenidate Efficacy in Treating Apathy in Alzheimer's Disease: Insights from the ADMET 2 trial
20250 citationsauthor #10
Predicting the progression of MCI and Alzheimer's disease on structural brain integrity and other features with machine learning.
20254 citationsauthor #412
Dissecting human cortical similarity networks across the lifespan.
202510 citationsauthor #204
Cognitive Effects of Combined Aerobic Exercise and Cognitive Training in Older Adults with Mild Cognitive Impairment
20250 citationsauthor #5
Blood biomarkers for Alzheimer's disease are correlated with treatment outcomes in a randomized trial assessing the effects of escitalopram on agitation
20250 citationsauthor #6
Voxel-wise insights into early Alzheimer’s disease pathology progression: the association with APOE and memory decline
20250 citationsauthor #138
Sustained clinically meaningful efficacy and consistent safety in patients with agitation associated with dementia due to Alzheimer’s disease treated with brexpiprazole: a 24‐week post hoc analysis
20250 citationsauthor #1
Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease
20254 citationsauthor #28
A US-based practitioner’s guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer’s dementia – recommendations of an expert, multispecialty advisory panel
20251 citationsauthor #4
Sleep variables in the S‐CitAD RCT of escitalopram for agitation in Alzheimer's disease
20250 citationsauthor #3
Predictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease
20240 citationsauthor #11
Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer’s Disease Neuroimaging Initiative cohort
202420 citationsauthor #141
Sex differences in interacting genetic and functional connectivity biomarkers in Alzheimer’s disease
20243 citationsauthor #140
Clinical Manifestations.
20241 citationsauthor #13
Correction: Polygenic effects on the risk of Alzheimer’s disease in the Japanese population
20240 citationsauthor #101
Complementary value of molecular, phenotypic, and functional aging biomarkers in dementia prediction
20244 citationsauthor #136
Local molecular and connectomic contributions of tau-related neurodegeneration
20243 citationsauthor #143
Robust, fully-automated assessment of cerebral perivascular spaces and white matter lesions: a multicentre MRI longitudinal study of their evolution and association with risk of dementia and accelerated brain atrophy
202414 citationsauthor #137
Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
20242 citationsauthor #11
Escitalopram for Agitation in Alzheimer’s Dementia
20243 citationsauthor #10
APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics
202415 citationsauthor #2
Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer’s disease: a novel small molecule with disease modifying potential
20242 citationsauthor #4
A novel spatiotemporal graph convolutional network framework for functional connectivity biomarkers identification of Alzheimer’s disease
202415 citationsauthor #152
Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
20240 citationsauthor #13
Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration
20241 citationsauthor #137
Polygenic effects on the risk of Alzheimer’s disease in the Japanese population
202413 citationsauthor #101
Phase 3 Trial of Oral Anti‐Amyloid Agent ALZ‐801/Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Characteristics and Prevalence of Comorbid Cerebral Amyloid Angiopathy
20240 citationsauthor #5
FC16: Timing and Duration of Adverse Events During Treatment of Agitation in Alzheimer’s Dementia with Brexpiprazole: Pooled Results From Three Phase 3 Trials
20240 citationsauthor #7
Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease.
20246 citationsauthor #4
iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer’s disease
202416 citationsauthor #8
Results of SIGNAL‐AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with mild Alzheimer’s dementia
20242 citationsauthor #9
Erratum to: Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease Suggest Disease Modification Potential
20240 citationsauthor #2
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2
20242 citationsauthor #10
Prevalence of Cerebral Microhemorrhages and Cortical Superficial Siderosis in APOE4/4 Homozygotes with Early Alzheimer’s disease: Baseline Findings from Phase 3 Trial of Oral ALZ‐801 in APOE4/4 Homozygotes (APOLLOE4)
20231 citationsauthor #4
Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
20230 citationsauthor #15
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease
202317 citationsauthor #4
Prognostic relevance of gait-related cognitive functions for dementia conversion in amnestic mild cognitive impairment
202311 citationsauthor #105
Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data
202312 citationsauthor #269
Author Correction: Predicting Alzheimer’s disease progression using multi-modal deep learning approach
20230 citationsauthor #181
Cost Consequence Analysis of ADMET 2
20230 citationsauthor #13
Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders
20230 citationsauthor #12
P105: Measuring clinically relevant change in apathy symptoms in ADMET 2
20230 citationsauthor #9
Prognostic value of plasma biomarkers in a clinical trial of mild‐to‐moderate Alzheimer’s Disease
20230 citationsauthor #17
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
202315 citationsauthor #76
Correlation between changes in apathy and global cognition in apathetic associated with Alzheimer's disease: analysis of the Apathy Dementia Methylphenidate 2 (ADMET 2) clinical trial
20231 citationsauthor #12
P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial
20230 citationsauthor #12
Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial
20230 citationsauthor #11
Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer’s disease: an exploratory study of ^18F-FDG-PET
202312 citationsauthor #149
Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
20233 citationsauthor #13
Prevalence of Amyloid-Related Imaging Abnormalities in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Findings from Ongoing Clinical Trials of Oral Anti-Amyloid Agent ALZ-801 (Valiltramiprosate) (P5-6.003)
20234 citationsauthor #5
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction
202349 citationsauthor #156
Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease
202237 citationsauthor #139
Baseline EMBARK Data From EMERGE, ENGAGE, and PRIME Participants in the EMBARK Redosing Study (N3.002)
20221 citationsauthor #4
Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment
202212 citationsauthor #150
Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease
20220 citationsauthor #186
Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume
202225 citationsauthor #147
ALZ‐NET: Using Real World Evidence to Inform the Future of Alzheimer’s Treatment and Care
20223 citationsauthor #17
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
202293 citationsauthor #140
Alzheimer's disease and related dementias: From risk factors to disease pathogenesis
20220 citationsauthor #1
The Polygenic Risk Score Knowledge Base offers a centralized online repository for calculating and contextualizing polygenic risk scores
20228 citationsauthor #250
A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease
202221 citationsauthor #120
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
202237 citationsauthor #156
Item-Level Analysis of Clinical Measures in Patients With Early Symptomatic Alzheimer’s Disease Following Treatment With High-Dose Aducanumab in the Phase 3 EMERGE Study (P1-1.Virtual)
20220 citationsauthor #10
Effect of online tDCS to left somatomotor cortex on neuropsychiatric symptoms among older adults at risk for dementia.
202213 citationsauthor #4
Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial
20225 citationsauthor #11
Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients
202219 citationsauthor #97
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
2021548 citationsauthor #1
Author Correction: Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease
20216 citationsauthor #140
Targeting autonomic flexibility to enhance cognitive training outcomes in older adults with mild cognitive impairment: study protocol for a randomized controlled trial
202116 citationsauthor #6
Diagnostic criteria for apathy in neurocognitive disorders
2021136 citationsauthor #21
The trend of disruption in the functional brain network topology of Alzheimer’s disease
202136 citationsauthor #199
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
202189 citationsauthor #9
Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer’s disease
202128 citationsauthor #74
Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization
202122 citationsauthor #178
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
2021571 citationsauthor #143

TIMELINE

1996 14 citations

1997 116 citations

1999 0 citations

2000 8 citations

2001 229 citations

2002 75 citations

2003 56 citations

2004 0 citations

2005 216 citations

2006 484 citations

2007 61 citations

2008 372 citations

2009 55 citations

2010 1,333 citations

2011 530 citations

2012 997 citations

2013 350 citations

2014 2,643 citations

2015 707 citations

2016 1,846 citations

2017 415 citations

2018 436 citations

2019 538 citations

2020 991 citations

2021 1,656 citations

2022 274 citations

2023 125 citations

2024 122 citations

2025 141 citations

2026 1 citations

Unknown 173 citations

A. Porsteinsson

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT